Literature DB >> 33621703

Re-emphasizing early Alzheimer's disease pathology starting in select entorhinal neurons, with a special focus on mitophagy.

Asgeir Kobro-Flatmoen1, Maria Jose Lagartos-Donate2, Yahyah Aman2, Paul Edison3, Menno P Witter4, Evandro F Fang5.   

Abstract

The entorhinal-hippocampal system contains distinct networks subserving declarative memory. This system is selectively vulnerable to changes of ageing and pathological processes. The entorhinal cortex (EC) is a pivotal component of this memory system since it serves as the interface between the neocortex and the hippocampus. EC is heavily affected by the proteinopathies of Alzheimer's disease (AD). These appear in a stereotypical spatiotemporal manner and include increased levels of intracellular amyloid-beta Aβ (iAβ), parenchymal deposition of Aβ plaques, and neurofibrillary tangles (NFTs) containing abnormally processed Tau. Increased levels of iAβ and the formation of NFTs are seen very early on in a population of neurons belonging to EC layer II (EC LII), and recent evidence leads us to believe that this population is made up of highly energy-demanding reelin-positive (RE+) projection neurons. Mitochondria are fundamental to the energy supply, metabolism, and plasticity of neurons. Evidence from AD postmortem brain tissues supports the notion that mitochondrial dysfunction is one of the initial pathological events in AD, and this is likely to take place in the vulnerable RE + EC LII neurons. Here we review and discuss these notions, anchored to the anatomy of AD, and formulate a hypothesis attempting to explain the vulnerability of RE + EC LII neurons to the formation of NFTs. We attempt to link impaired mitochondrial clearance to iAβ and signaling involving both apolipoprotein 4 and reelin, and argue for their relevance to the formation of NFTs specifically in RE + EC LII neurons during the prodromal stages of AD. We believe future studies on these interactions holds promise to advance our understanding of AD etiology and provide new ideas for drug development.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Entorhinal cortex; Medial temporal lobe; Mitochondria; Mitophagy; Reelin

Mesh:

Substances:

Year:  2021        PMID: 33621703     DOI: 10.1016/j.arr.2021.101307

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  13 in total

Review 1.  Mitophagy in Alzheimer's disease: Molecular defects and therapeutic approaches.

Authors:  Arnaud Mary; Fanny Eysert; Frédéric Checler; Mounia Chami
Journal:  Mol Psychiatry       Date:  2022-06-03       Impact factor: 15.992

Review 2.  Autophagy in health and disease: From molecular mechanisms to therapeutic target.

Authors:  Guang Lu; Yu Wang; Yin Shi; Zhe Zhang; Canhua Huang; Weifeng He; Chuang Wang; Han-Ming Shen
Journal:  MedComm (2020)       Date:  2022-07-10

3.  P. edulis Extract Protects Against Amyloid-β Toxicity in Alzheimer's Disease Models Through Maintenance of Mitochondrial Homeostasis via the FOXO3/DAF-16 Pathway.

Authors:  Shu-Qin Cao; Yahyah Aman; Evandro F Fang; Tewin Tencomnao
Journal:  Mol Neurobiol       Date:  2022-06-23       Impact factor: 5.682

4.  Aβ-induced mitochondrial dysfunction in neural progenitors controls KDM5A to influence neuronal differentiation.

Authors:  Dong Kyu Kim; Hyobin Jeong; Jingi Bae; Moon-Yong Cha; Moonkyung Kang; Dongjin Shin; Shinwon Ha; Seung Jae Hyeon; Hokeun Kim; Kyujin Suh; Mi-Sun Choi; Hoon Ryu; Seong-Woon Yu; Jong-Il Kim; Yeon-Soo Kim; Sang-Won Lee; Daehee Hwang; Inhee Mook-Jung
Journal:  Exp Mol Med       Date:  2022-09-02       Impact factor: 12.153

5.  Increased CSF-decorin predicts brain pathological changes driven by Alzheimer's Aβ amyloidosis.

Authors:  Richeng Jiang; Una Smailovic; Hazal Haytural; Betty M Tijms; Hao Li; Robert Mihai Haret; Ganna Shevchenko; Gefei Chen; Axel Abelein; Johan Gobom; Susanne Frykman; Misaki Sekiguchi; Ryo Fujioka; Naoto Watamura; Hiroki Sasaguri; Sofie Nyström; Per Hammarström; Takaomi C Saido; Vesna Jelic; Stina Syvänen; Henrik Zetterberg; Bengt Winblad; Jonas Bergquist; Pieter Jelle Visser; Per Nilsson
Journal:  Acta Neuropathol Commun       Date:  2022-07-04       Impact factor: 7.578

Review 6.  Defective mitophagy and the etiopathogenesis of Alzheimer's disease.

Authors:  Kuan Zeng; Xuan Yu; Yacoubou Abdoul Razak Mahaman; Jian-Zhi Wang; Rong Liu; Yi Li; Xiaochuan Wang
Journal:  Transl Neurodegener       Date:  2022-06-03       Impact factor: 9.883

Review 7.  Mechanisms of Mitochondrial Malfunction in Alzheimer's Disease: New Therapeutic Hope.

Authors:  Showkat Ul Nabi; Andleeb Khan; Ehraz Mehmood Siddiqui; Muneeb U Rehman; Saeed Alshahrani; Azher Arafah; Sidharth Mehan; Rana M Alsaffar; Athanasios Alexiou; Bairong Shen
Journal:  Oxid Med Cell Longev       Date:  2022-05-14       Impact factor: 7.310

8.  Amelioration of Alzheimer's disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow.

Authors:  Chenglong Xie; Xu-Xu Zhuang; Zhangming Niu; Ruixue Ai; Sofie Lautrup; Shuangjia Zheng; Yinghui Jiang; Ruiyu Han; Tanima Sen Gupta; Shuqin Cao; Maria Jose Lagartos-Donate; Cui-Zan Cai; Li-Ming Xie; Domenica Caponio; Wen-Wen Wang; Tomas Schmauck-Medina; Jianying Zhang; He-Ling Wang; Guofeng Lou; Xianglu Xiao; Wenhua Zheng; Konstantinos Palikaras; Guang Yang; Kim A Caldwell; Guy A Caldwell; Han-Ming Shen; Hilde Nilsen; Jia-Hong Lu; Evandro F Fang
Journal:  Nat Biomed Eng       Date:  2022-01-06       Impact factor: 29.234

9.  Relevance of a Novel Circuit-Level Model of Episodic Memories to Alzheimer's Disease.

Authors:  Krisztián A Kovács
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

Review 10.  Impairment of the autophagy-lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potential.

Authors:  Wei Zhang; Chengchao Xu; Jichao Sun; Han-Ming Shen; Jigang Wang; Chuanbin Yang
Journal:  Acta Pharm Sin B       Date:  2022-01-21       Impact factor: 14.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.